Canagliflozin did not statistically significantly increase the risk for lower-limb amputations, fractures, acute kidney in- jury, or hyperkalemia but did increase the risk for diabetic ketoacidosis (2.2 and 0.2 events per 1000 patient-years in the canagliflozin and placebo groups, respectively)
* *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
Boers E, Barrett MA, Benjafield AV, et al
SteinbergGRValvanoCMDe NardoWWattMJ
44 mmol/kg dry muscle)
The interface remembers recent activity, surfacing your last-played titles and saved favorites